Look back at pharma news to Mar 24

25 March 2017

By Barbara Obstoj-Cardwell. Editor

The new US President Donald Trump suffered a major defeat on Friday, as his flagship legislation to repeal what is commonly referred to as Obamacare, failed to gain sufficient support. Also making headlines was Eli Lilly’s planned investment on infrastructure; a promising abuse-deterrent opioid drug; recommended European approval of a new hemophilia drug; and a setback for Novartis’ serelaxin.

The withdrawal of new healthcare legislation in the USA signalled the failure of Mr Trump’s exhaustive last-minute efforts to cajole lawmakers, raising questions about whether he could unify Republicans behind his pro-growth legislative goals of tax reform and infrastructure spending, stated the Financial Times. Mr Trump said he was 10-15 votes short of the majority needed to pass the bill, but declined to criticise Republicans. Instead he sought to blame Democrats, even though his party has enough lawmakers to pass legislation if it stays united.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK